CD4 and myeloid sarcoma: The deep involvement of a dysregulated immune system in MS is also supported by the efficacy of drugs targeting T- and B-cell functions in the treatment of the disease, as well as by the numerous studies indicating CD4+ and CD8+ T cells as strong contributors to the pathogenic process [11,12,13,14].